跳转至内容
Merck
CN
  • Screening and confirmation of myo-inositol trispyrophosphate (ITPP) in human urine by hydrophilic interaction liquid chromatography high resolution / high accuracy mass spectrometry for doping control purposes.

Screening and confirmation of myo-inositol trispyrophosphate (ITPP) in human urine by hydrophilic interaction liquid chromatography high resolution / high accuracy mass spectrometry for doping control purposes.

Drug testing and analysis (2014-07-30)
Christian Görgens, Sven Guddat, Wilhelm Schänzer, Mario Thevis
摘要

Myo-inositol trispyrophosphate (ITPP) is a novel allosteric effector of haemoglobin with high permeation selectivity across the red blood cell plasma membrane. Due to its potential to reduce the oxygen affinity of haemoglobin, ITPP application results in an enhanced oxygen release in hypoxic tissues. Therefore, ITPP is being examined for the treatment of numerous illnesses that involve hypoxia, such as cardiovascular diseases, cancer or Alzheimer's disease. Similar to the prohibited substance Efaproxiral®, ITPP increases maximal exercise capacity in mice, providing high potential to be misused in sports. To keep up with cheating athletes, a fast and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for screening and confirmation of ITPP in human urine for doping control purposes was developed. According to the molecule's distinct hydrophilic properties, extraction from complex biological matrices is challenging and conventional reversed phase liquid chromatography (RPLC) separations are not suitable for its detection. Therefore an approach based on hydrophilic interaction liquid chromatography (HILIC) Orbitrap mass spectrometry was established. The methodology was fully validated for qualitative purposes. Screening and confirmation assay are characterized by satisfactory specificity and robustness, adequate intra-day (screening: 4.9-8.1%; confirmation: 2.0-6.7%) and inter-day precision (screening: 4.6-9.1%; confirmation: 1.8-6.6%), excellent linear correlations (>0.99) with sufficient LLOD in the sub ng/mL range (screening: 15 ng/mL; confirmation: 1 ng/mL). In addition it could be shown that ITPP is stable in human urine under the mandatory storage period and conditions for doping control laboratories. To our knowledge, this is the first validated 'dilute-and-inject' LC-MS/MS method for the reliable detection of ITPP in human urine.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
乙腈, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
甲醇, suitable for HPLC, ≥99.9%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
乙酸, glacial, ACS reagent, ≥99.7%
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
乙酸, glacial, ReagentPlus®, ≥99%
Sigma-Aldrich
甲醇, HPLC Plus, ≥99.9%
Sigma-Aldrich
乙腈, ACS reagent, ≥99.5%
Sigma-Aldrich
乙酸铵, ACS reagent, ≥97%
Sigma-Aldrich
乙腈, anhydrous, 99.8%
Sigma-Aldrich
甲醇, anhydrous, 99.8%
Sigma-Aldrich
乙酸铵, ≥99.99% trace metals basis
Supelco
乙酸铵, LiChropur, eluent additive for LC-MS
Sigma-Aldrich
乙腈, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
乙酸, glacial, ≥99.99% trace metals basis
Sigma-Aldrich
乙腈, ≥99.9% (GC)
Sigma-Aldrich
乙酸, glacial, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8%
Sigma-Aldrich
乙酸 溶液, suitable for HPLC
Sigma-Aldrich
乙酸, glacial, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.8-100.5%
Sigma-Aldrich
甲醇, Laboratory Reagent, ≥99.6%
Sigma-Aldrich
甲醇, suitable for HPLC, gradient grade, suitable as ACS-grade LC reagent, ≥99.9%
Sigma-Aldrich
甲醇, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8% (GC)
Sigma-Aldrich
甲醇, ACS spectrophotometric grade, ≥99.9%
Sigma-Aldrich
乙酸铵, Molecular Biology, ≥98%
Sigma-Aldrich
甲醇, ACS reagent, ≥99.8%
Sigma-Aldrich
肌醇 -肌醇, ≥99% (GC), BioReagent
Sigma-Aldrich
肌醇 -肌醇, ≥99%
Sigma-Aldrich
乙腈, suitable for HPLC-GC, ≥99.8% (GC)
Sigma-Aldrich
乙酸铵 溶液, Molecular Biology, 7.5 M
USP
木精, United States Pharmacopeia (USP) Reference Standard